367 related articles for article (PubMed ID: 30049473)
1. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism.
Fukagawa M; Shimazaki R; Akizawa T;
Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473
[TBL] [Abstract][Full Text] [Related]
2. Development of evocalcet for unmet needs among calcimimetic agents.
Hamano N; Endo Y; Kawata T; Fukagawa M
Expert Rev Endocrinol Metab; 2020 Sep; 15(5):299-310. PubMed ID: 32552012
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of evocalcet for secondary hyperparathyroidism in Japanese hemodialysis patients.
Shigematsu T; Shimazaki R; Fukagawa M; Akizawa T;
Clin Exp Nephrol; 2019 Feb; 23(2):258-267. PubMed ID: 30159688
[TBL] [Abstract][Full Text] [Related]
5. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study.
Akizawa T; Shimazaki R; Fukagawa M;
PLoS One; 2018; 13(10):e0204896. PubMed ID: 30379826
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA
Tokunaga S; Endo Y; Kawata T
Nihon Yakurigaku Zasshi; 2019; 154(1):35-43. PubMed ID: 31308348
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Efficacy and Safety of Evocalcet in Japanese Patients with Secondary Hyperparathyroidism Receiving Hemodialysis.
Yokoyama K; Shimazaki R; Fukagawa M; Akizawa T;
Sci Rep; 2019 Apr; 9(1):6410. PubMed ID: 31015494
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism.
Ni Z; Liang X; Wu CC; Jin K; Kim YL; Lu KC; Chan TM; Fukagawa M; Kinoshita J; Nagai C; Kojima M; Yu X;
Kidney Int Rep; 2023 Nov; 8(11):2294-2306. PubMed ID: 38025238
[TBL] [Abstract][Full Text] [Related]
9. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
10. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
[TBL] [Abstract][Full Text] [Related]
12. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients.
Tsuruya K; Shimazaki R; Fukagawa M; Akizawa T;
Clin Exp Nephrol; 2019 Jun; 23(6):739-748. PubMed ID: 30955188
[TBL] [Abstract][Full Text] [Related]
14. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
Bucharles SGE; Barreto FC; Riella MC
J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
[TBL] [Abstract][Full Text] [Related]
15. Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism.
Sakai M; Tokunaga S; Kawai M; Murai M; Kobayashi M; Kitayama T; Saeki S; Kawata T
PLoS One; 2020; 15(4):e0232428. PubMed ID: 32343734
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of Cinacalcet on secondary hyperparathyroidism in Chinese chronic kidney disease patients receiving hemodialysis.
Mei C; Chen N; Ding X; Yu X; Wang L; Qian J; Wang M; Jiang G; Li X; Hou F; Zuo L; Wang N; Liu H
Hemodial Int; 2016 Oct; 20(4):589-600. PubMed ID: 26940692
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics, and Safety of the Novel Calcimimetic Agent Evocalcet in Healthy Japanese Subjects: First-in-Human Phase I Study.
Akizawa T; Shimazaki R; Shiramoto M; Fukagawa M;
Clin Drug Investig; 2018 Oct; 38(10):945-954. PubMed ID: 30168004
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of cinacalcet: a randomized, open label study in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Susantitaphong P; Vadcharavivad S; Susomboon T; Singhan W; Dumrongpisutikul N; Jakchairoongruang K; Eiam-Ong S; Praditpornsilpa K
Ren Fail; 2019 Nov; 41(1):326-333. PubMed ID: 31014177
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of evocalcet in treatment of secondary hyperparathyroidism in chronic kidney disease on hemodialysis patients: A protocol for a systematic review and meta-analysis.
Xie J; Li X; Chen Y; Chen M; Mao N; Fan J
Medicine (Baltimore); 2020 Nov; 99(46):e22566. PubMed ID: 33181644
[TBL] [Abstract][Full Text] [Related]
20. [Retrospective assessment of effective and safety of cinacalcet for the treatment of secondary hyperparathyroidism depending on basal iPTH level].
Mercadal Orfila G; Blasco Mascaró I
Farm Hosp; 2012; 36(1):11-5. PubMed ID: 21514862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
